What is the clinical evidence from this study?

Study design: Cohort. Population: Prostate cancer (n=7497). Intervention: Prior PSA screening vs. No prior PSA screening. Primary outcome: Early-stage (I-II) diagnosis (adjusted OR 1.49, 95% CI 1.34-1.66, p=<0.001).

What does this research mean for the field?

Prior prostate-specific antigen (PSA) screening is associated with significantly higher odds of an early-stage prostate cancer diagnosis across all adult age groups, including those outside standard routine screening recommendations. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

This research investigates whether prior PSA screening impacts the stage at which prostate cancer is diagnosed.

May 30, 2026Journal of Clinical Oncology

Prior PSA screening linked to ~49% higher odds of early-stage prostate cancer diagnosis.

Q: What are the key findings of this study?

Prior PSA screening was associated with higher odds of an early-stage diagnosis at first prostate cancer diagnosis compared to no prior screening (adjusted OR 1.49; 95% CI 1.34-1.66; p<0.001).

Q: What does this research mean for the field?

Prior prostate-specific antigen (PSA) screening is associated with significantly higher odds of an early-stage prostate cancer diagnosis across all adult age groups, including those outside standard routine screening recommendations. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

Q: What question did this study set out to answer?

This research investigates whether prior PSA screening impacts the stage at which prostate cancer is diagnosed.

View Full Paper

Ask AI

Bookmark

Why the study?

To evaluate whether evidence of prior PSA screening is associated with earlier stage at first prostate cancer diagnosis.

Does prior PSA screening improve the odds of early-stage diagnosis in adults with prostate cancer?

Population

7,497 adults aged ≥40 years with a first-recorded prostate cancer diagnosis

Comparison

Prior PSA screening vs no prior PSA screening

Design

Retrospective EHR cohort study

Key result

Prior PSA screening was associated with higher odds of an early-stage diagnosis at first prostate cancer diagnosis compared to no prior screening (adjusted OR 1.49; 95% CI 1.34-1.66; p<0.001).

Authors

DDDuy Do KFKaren Farrar NMNina B. Masters

Discussion

Member takes

Overview

Prior PSA screening may support earlier detection discussions in eligible men; extends real-world data aligning with USPSTF guidelines but requires prospective confirmation.

Key Points

This research investigates whether prior PSA screening impacts the stage at which prostate cancer is diagnosed.
Analyzed electronic health records (EHR) from Truveta Data for adults aged ≥40 with prostate cancer diagnosed from 2018–2025.
Categorized diagnosis stage as early (I–II) or late (III–IV) and examined prior PSA screenings conducted 3 years to 6 months prior.
Applied multivariable logistic regression to assess the relationship between prior PSA screening and early-stage diagnosis, adjusting for various factors.
Out of 1,038,594 patients, 7,497 met study criteria with 55.3% having prior PSA screening.
Early-stage disease occurred in 43.8% of those screened versus 39.3% of those not screened (p < 0.001).
Adjusted for factors, prior screening was linked to higher odds of early-stage diagnosis (OR 1.49, 95% CI 1.34-1.66).

Study Design

Type

Cohort (n=7,497)

Multicenter

Yes

Structured PICO

Does prior PSA screening improve the odds of early-stage diagnosis in adults with prostate cancer?

Population

7,497 adults aged ≥40 years with a first-recorded prostate cancer diagnosis in 2018–2025 (mean age 73 years) from a US EHR cohort. Excluded if any chemotherapy or cancer treatment before index.

Intervention

Prior PSA screening (any PSA screening recorded three years to six months before the index diagnosis)

Comparator

No prior PSA screening

Outcome

Early-stage (I–II) versus late-stage (III–IV) at diagnosis

Main Result

Effect estimate: adjusted OR 1.49 (95% CI 1.34-1.66)

Absolute Event Rate: 43.8% vs 39.3%

p-value: p=<0.001

Prior PSA screening is associated with higher odds of earlier-stage prostate cancer diagnosis across all age groups, including those where routine screening is not generally recommended.

Cite This Study

Do et al. (2026) conducted a cohort in Prostate cancer (n=7,497). Prior PSA screening vs. No prior PSA screening was evaluated on Early-stage (I-II) diagnosis (adjusted OR 1.49, 95% CI 1.34-1.66, p=<0.001). Prior PSA screening was associated with higher odds of an early-stage diagnosis at first prostate cancer diagnosis compared to no prior screening (adjusted OR 1.49; 95% CI 1.34-1.66; p<0.001).

synapsesocial.com/papers/6a1a7fce0307b78509431fbb https://doi.org/10.1200/jco.2026.44.16_suppl.e17071

View Full Paper

Ask AI

Bookmark

May 30, 2026Journal of Clinical Oncology

Prior PSA screening linked to ~49% higher odds of early-stage prostate cancer diagnosis.

View Full Paper

Ask AI

Bookmark

Why the study?

To evaluate whether evidence of prior PSA screening is associated with earlier stage at first prostate cancer diagnosis.

Does prior PSA screening improve the odds of early-stage diagnosis in adults with prostate cancer?

Population

7,497 adults aged ≥40 years with a first-recorded prostate cancer diagnosis

Comparison

Prior PSA screening vs no prior PSA screening

Design

Retrospective EHR cohort study

Key result

Prior PSA screening was associated with higher odds of an early-stage diagnosis at first prostate cancer diagnosis compared to no prior screening (adjusted OR 1.49; 95% CI 1.34-1.66; p<0.001).

Authors

DDDuy Do KFKaren Farrar NMNina B. Masters

Discussion

Member takes

Overview

Prior PSA screening may support earlier detection discussions in eligible men; extends real-world data aligning with USPSTF guidelines but requires prospective confirmation.

Key Points

This research investigates whether prior PSA screening impacts the stage at which prostate cancer is diagnosed.
Analyzed electronic health records (EHR) from Truveta Data for adults aged ≥40 with prostate cancer diagnosed from 2018–2025.
Categorized diagnosis stage as early (I–II) or late (III–IV) and examined prior PSA screenings conducted 3 years to 6 months prior.
Applied multivariable logistic regression to assess the relationship between prior PSA screening and early-stage diagnosis, adjusting for various factors.
Out of 1,038,594 patients, 7,497 met study criteria with 55.3% having prior PSA screening.
Early-stage disease occurred in 43.8% of those screened versus 39.3% of those not screened (p < 0.001).
Adjusted for factors, prior screening was linked to higher odds of early-stage diagnosis (OR 1.49, 95% CI 1.34-1.66).

Study Design

Type

Cohort (n=7,497)

Multicenter

Yes

Structured PICO

Does prior PSA screening improve the odds of early-stage diagnosis in adults with prostate cancer?

Population

7,497 adults aged ≥40 years with a first-recorded prostate cancer diagnosis in 2018–2025 (mean age 73 years) from a US EHR cohort. Excluded if any chemotherapy or cancer treatment before index.

Intervention

Prior PSA screening (any PSA screening recorded three years to six months before the index diagnosis)

Comparator

No prior PSA screening

Outcome

Early-stage (I–II) versus late-stage (III–IV) at diagnosis

Main Result

Effect estimate: adjusted OR 1.49 (95% CI 1.34-1.66)

Absolute Event Rate: 43.8% vs 39.3%

p-value: p=<0.001

Prior PSA screening is associated with higher odds of earlier-stage prostate cancer diagnosis across all age groups, including those where routine screening is not generally recommended.

Cite This Study

synapsesocial.com/papers/6a1a7fce0307b78509431fbb https://doi.org/10.1200/jco.2026.44.16_suppl.e17071

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark